Beta Bionics [BBNX] vs Enovis [ENOV] Detailed Stock Comparison

Beta Bionics

NASDAQ
Loading...

Enovis

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Beta Bionics wins in 7 metrics, Enovis wins in 10 metrics, with 0 ties. Enovis appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricBeta BionicsEnovisBetter
P/E Ratio (TTM)-17.42-2.14Beta Bionics
Price-to-Book Ratio3.210.71Enovis
Debt-to-Equity Ratio2.2256.75Beta Bionics
PEG Ratio3.90-0.02Enovis
EV/EBITDA-11.828.97Beta Bionics
Profit Margin (TTM)-94.04%-37.80%Enovis
Operating Margin (TTM)-85.52%2.41%Enovis
EBITDA Margin (TTM)N/A2.41%N/A
Return on Equity22.32%-28.25%Beta Bionics
Return on Assets (TTM)-36.59%0.89%Enovis
Free Cash Flow (TTM)$-51.67M$-67.21MBeta Bionics
1-Year Return-6.51%-21.31%Beta Bionics
Price-to-Sales Ratio (TTM)12.400.84Enovis
Enterprise Value$724.61M$3.25BEnovis
EV/Revenue Ratio9.291.49Enovis
Gross Profit Margin (TTM)53.80%59.29%Enovis
Revenue per Share (TTM)$4$39Enovis
Earnings per Share (Diluted)$-1.69$-14.95Beta Bionics
Beta (Stock Volatility)N/A1.80N/A
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Beta Bionics vs Enovis Stock Performance Analysis

Loading Price Chart...

Beta Bionics
Enovis
Beta Bionics Stock Overview | Enovis Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Beta Bionics-1.39%13.98%13.11%64.64%106.69%-5.80%
Enovis-2.37%6.77%4.44%-4.84%-5.24%-27.72%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Beta Bionics-6.51%-6.51%-6.51%-6.51%-6.51%-6.51%
Enovis-21.31%-30.29%-42.20%-39.91%19.48%-9.24%

News Based Sentiment: Beta Bionics vs Enovis

Beta Bionics

News based Sentiment: POSITIVE

Beta Bionics demonstrated strong Q2 earnings, exceeding expectations, and secured a significant analyst upgrade. While insider selling is a concern, the influx of institutional investment and strategic partnership with Abbott suggest a positive trajectory for the company, making this a noteworthy month for investors.

View Beta Bionics News Sentiment Analysis

Enovis

News based Sentiment: POSITIVE

October was a notably positive month for Enovis, marked by significant analyst upgrades, substantial insider buying activity, and a clear strategic direction under its new CEO. These developments suggest growing confidence in the company's future prospects and potential for growth, making it a significant month for investors.

View Enovis News Sentiment Analysis

Performance & Financial Health Analysis: Beta Bionics vs Enovis

MetricBBNXENOV
Market Information
Market Cap i$1.10B$1.83B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i803,623615,380
90 Day Avg. Volume i938,151899,257
Last Close$21.95$31.26
52 Week Range$8.89 - $26.66$25.47 - $49.83
% from 52W High-17.67%-37.27%
All-Time High$26.66 (Sep 12, 2025)$129.72 (Jun 09, 2014)
% from All-Time High-17.67%-75.90%
Growth Metrics
Quarterly Revenue Growth0.54%0.08%
Quarterly Earnings Growth0.80%0.08%
Financial Health
Profit Margin (TTM) i-0.94%-0.38%
Operating Margin (TTM) i-0.86%0.02%
Return on Equity (TTM) i0.22%-0.28%
Debt to Equity (MRQ) i2.2256.75
Cash & Liquidity
Book Value per Share (MRQ)$6.94$45.11
Cash per Share (MRQ)$5.75$0.77
Operating Cash Flow (TTM) i$-57,461,000$188.06M
Levered Free Cash Flow (TTM) i$-54,756,000$65.68M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/A$0.00

Valuation & Enterprise Metrics Analysis: Beta Bionics vs Enovis

MetricBBNXENOV
Price Ratios
P/E Ratio (TTM) i-17.42-2.14
Forward P/E i-12.3910.13
PEG Ratio i3.90-0.02
Price to Sales (TTM) i12.400.84
Price to Book (MRQ) i3.210.71
Market Capitalization
Market Capitalization i$1.10B$1.83B
Enterprise Value i$724.61M$3.25B
Enterprise Value Metrics
Enterprise to Revenue i9.291.49
Enterprise to EBITDA i-11.828.97
Risk & Other Metrics
Beta iN/A1.80
Book Value per Share (MRQ) i$6.94$45.11

Financial Statements Comparison: Beta Bionics vs Enovis

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)BBNXENOV
Revenue/Sales i$17.64M$564.55M
Cost of Goods Sold i$8.67M$229.85M
Gross Profit i$8.97M$334.70M
Research & Development i$7.59M$30.70M
Operating Income (EBIT) i$-18.64M$-16.08M
EBITDA i$-5.59M$55.91M
Pre-Tax Income i$-28.66M$-25.65M
Income Tax iN/A$10.80M
Net Income (Profit) i$-28.66M$-36.55M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)BBNXENOV
Cash & Equivalents i$42.45M$38.46M
Total Current Assets i$261.92M$1.22B
Total Current Liabilities i$16.49M$477.42M
Long-Term Debt i$5.45M$1.42B
Total Shareholders Equity i$313.75M$2.62B
Retained Earnings i$-325.39M$-338.99M
Property, Plant & Equipment i$13.04M$492.24M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)BBNXENOV
Operating Cash Flow i$-24.83M$-1.07M
Capital Expenditures i$-333,000$-43.26M
Free Cash Flow i$-20.31M$-44.86M
Debt Repayment iN/A$-15.44M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBBNXENOV
Shares Short i3.88M6.93M
Short Ratio i5.527.31
Short % of Float i0.10%0.18%
Average Daily Volume (10 Day) i803,623615,380
Average Daily Volume (90 Day) i938,151899,257
Shares Outstanding i42.86M55.88M
Float Shares i21.42M56.42M
% Held by Insiders i0.01%0.02%
% Held by Institutions i1.09%1.21%

Dividend Analysis & Yield Comparison: Beta Bionics vs Enovis

MetricBBNXENOV
Last 12-Month Dividend iN/A$0.00
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/A$0.00
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/A$0.00
Ex-Dividend DateN/AN/A